Psoriasis Vulgaris

Immunology
4
Pipeline Programs
6
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 7 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
1
tofacitinib ointment 20 mg/gPhase 21 trial
Infliximab [infliximab biosimilar 3]N/A3 trials
Active Trials
NCT03885089Completed10Est. Mar 2024
NCT03885037Completed77Est. Nov 2024
NCT03884439Completed428Est. Feb 2024
+1 more trials
E
EisaiChina - Liaoning
1 program
1
0.03% E6201Phase 21 trial
Active Trials
NCT01268527Completed30Est. Dec 2010
Biotest Pharmaceuticals
Biotest PharmaceuticalsGermany - Dreieich
1 program
1
BT061Phase 21 trial
Active Trials
NCT01072383CompletedEst. Aug 2011
selectION Therapeutics
selectION TherapeuticsGermany - Planegg-Martinsried
1 program
1
si-544Phase 11 trial
Active Trials
NCT06191042CompletedEst. Jun 2025
Novartis
NovartisBASEL, Switzerland
2 programs
CosentyxN/A1 trial
PolysomnographyN/A1 trial
Active Trials
NCT05215561Completed36Est. Sep 2024
NCT05102474Completed24Est. Jul 2024
Verona Pharma
Verona PharmaUK - London
1 program
SecukinumabN/AMonoclonal Antibody1 trial
Active Trials
NCT03828643Completed156Est. Apr 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pfizertofacitinib ointment 20 mg/g
Eisai0.03% E6201
Biotest PharmaceuticalsBT061
selectION Therapeuticssi-544
NovartisPolysomnography
NovartisCosentyx
PfizerInfliximab [infliximab biosimilar 3]
Verona PharmaSecukinumab
PfizerInfliximab [infliximab biosimilar 3]
PfizerInfliximab [infliximab biosimilar 3]

Clinical Trials (10)

Total enrollment: 761 patients across 10 trials

NCT01831466Pfizertofacitinib ointment 20 mg/g

Tofacitinib Ointment For Chronic Plaque Psoriasis

Start: May 2013Est. completion: Sep 2014
Phase 2Completed
NCT01268527Eisai0.03% E6201

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Start: Mar 2010Est. completion: Dec 201030 patients
Phase 2Completed
NCT01072383Biotest PharmaceuticalsBT061

Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Start: Feb 2010Est. completion: Aug 2011
Phase 2Completed
NCT06191042selectION Therapeuticssi-544

A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

Start: Jan 2024Est. completion: Jun 2025
Phase 1Completed
NCT05102474NovartisPolysomnography

Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis

Start: Feb 2022Est. completion: Jul 202424 patients
N/ACompleted
NCT05215561NovartisCosentyx

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

Start: Feb 2022Est. completion: Sep 202436 patients
N/ACompleted
NCT03885089PfizerInfliximab [infliximab biosimilar 3]

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

Start: Oct 2019Est. completion: Mar 202410 patients
N/ACompleted
NCT03828643Verona PharmaSecukinumab

Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis

Start: Mar 2019Est. completion: Apr 2019156 patients
N/ACompleted
NCT03885037PfizerInfliximab [infliximab biosimilar 3]

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)

Start: Mar 2019Est. completion: Nov 202477 patients
N/ACompleted
NCT03884439PfizerInfliximab [infliximab biosimilar 3]

Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)

Start: Mar 2019Est. completion: Feb 2024428 patients
N/ACompleted

Related Jobs in Immunology

Regulatory Affairs Manager(Immunology), Korea

AbbVie
Seoul, Seoul
6h ago

Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)

AbbVie
Remote
7h ago

Product Specialist - Immunology

Johnson & Johnson
Kibbutz Shefayim, Center District, Israel
20h ago

Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine

Johnson & Johnson
Detroit, Michigan, United States
20h ago

Senior Medical Science Liaison, Dermatology - Indianapolis

Johnson & Johnson
Indianapolis, Indiana, United States
20h ago
$137K - $236K/yr

Field Reimbursement Manager - Rheumatology - Seattle, WA (North)

Johnson & Johnson
Seattle, Washington, United States of America
20h ago
$100K - $175K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

Related Indications

Rheumatoid Arthritis(475)Psoriasis(206)Ulcerative Colitis(151)Atopic Dermatitis(144)Crohn's Disease(140)Systemic Lupus Erythematosus(85)Arthritis, Rheumatoid(61)Plaque Psoriasis(53)Crohn Disease(49)Ankylosing Spondylitis(33)